In hepatitis B drug market, 'Viread (Tenofovir)' is showing an upward tendency

In hepatitis B drug market, 'Viread (Tenofovir)' is showing an upward tendency.

Its prescription cost exceeded already 10 billion won this year, and is increasing market share.

According to data from Ubist, it turned out that outpatient prescription of hepatitis B drug 'Viread' in Feb was 5.2 billion won.

Considering that Viread recorded prescription cost of 43 billion won last year, it seem...